Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/170764
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease |
Autor: | López-Millán, Belén; Díaz de la Guardia, Rafael; Roca-Ho, Heleia; García-Herrero, Carmen-María; Lavoie, Jessie R.; Rosu-Myles, Michael; González-Rey, Elena CSIC ORCID; O'Valle, Francisco; Criado, Gabriel CSIC ORCID; Delgado, M.; Menéndez, Pablo | Fecha de publicación: | 3-feb-2017 | Editor: | Springer Nature | Citación: | Experimental and Molecular Medicine | Resumen: | Thalidomide is an immunomodulatory drug (IMiD) with proven therapeutic action in several autoimmune/inflammatory diseases; however, its inherent high toxicity has led to the development of more powerful and safer thalidomide analogs, including lenalidomide and pomalidomide. These are new generation IMiDs that exhibit direct antitumor activity as well as anti-inflammatory/immunomodulatory properties, and are FDA-approved for the treatment of several hematological malignances. Here we investigated the potential therapeutic effects of lenalidomide and pomalidomide in several experimental murine models of autoimmune/inflammatory diseases: 2,4,6-trinitrobenzene sulfonic acid- and dextran sulfate sodium-induced inflammatory bowel disease and type II collagen-induced arthritis. Lenalidomide displayed a strong therapeutic effect in all these models of autoimmune/inflammatory diseases, while the effect of pomalidomide was less pronounced. In vitro experiments confirmed the immunosuppressive effect of both IMiDs on the proliferative response of stimulated human lymphocytes and on the balance of secreted cytokines toward an anti-inflammatory profile. We conclude that lenalidomide may offer a therapeutic opportunity against autoimmune/inflammatory diseases. | URI: | http://hdl.handle.net/10261/170764 | DOI: | 10.1038/emm.2016.143 | ISSN: | 1226-3613 | E-ISSN: | 2092-6413 |
Aparece en las colecciones: | (IPBLN) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Therapeutic_emm2016143.pdf | Original article | 1,71 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
9
checked on 14-abr-2024
SCOPUSTM
Citations
228
checked on 28-abr-2024
WEB OF SCIENCETM
Citations
18
checked on 26-feb-2024
Page view(s)
284
checked on 05-may-2024
Download(s)
215
checked on 05-may-2024